Tirzepatide’s clinical programme is set to double in size when a huge head-to-head outcome study gets under way. Costs will balloon too.
An analysis of the sellside’s consensus forecast changes reveals the winners and losers of 2019.
With Reva, Amaranth and Abbott out of the game, the pool of dissolving scaffold makers is shrinking.
The anti-CD19 MAb is Morphosys’s lead pipeline asset, and an imminent filing could see it approved next year.
Despite the recent flurry of gene therapy deals there is still a fairly extensive list of affordable companies out there.
An analysis of company disclosures reveals a sharp rise in US FDA-imposed halts on clinical work involving gene therapies.
The market for minimally invasive aortic implants is sewn up – can a tiny private group find a way in?
The orthopaedics sector has seen several sizeable mergers over the past decade. Might it see more?
The company plans to make the most of its head start with the Graves’ disease project teprotumumab, which is forecast to become its biggest product.